108 results on '"Travis S"'
Search Results
2. DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
3. OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial
4. DOP70 Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey
5. P124 Tissue Factor and Protease-Activated Receptor 2 associated genes are upregulated in patients with Inflammatory Bowel Disease
6. P285 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: European and US Patient and Health Care Professional Perspectives on the Broad Impact of Bowel Urgency in Ulcerative colitis
7. Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems
8. P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
9. OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
10. P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey
11. DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab
12. P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
13. P002 Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitis
14. P743 Relative association of bowel urgency improvement versus remission of stool frequency and rectal bleeding with Patient Global Rating of Severity or Change scores in moderately-to-severely active Ulcerative Colitis: An analysis from the LUCENT-1 and LUCENT-2 Phase 3 trials
15. P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index
16. DOP02 Single cell RNA sequencing of Ulcerative Colitis and Crohn's Disease tissue samples informs the selection of Triggering Receptors Expressed on Myeloid Cells 1 (TREM1) as a target for the treatment of Inflammatory Bowel Diseases
17. P802 Relationships between validated clinical, endoscopic and histological indices in ulcerative colitis
18. P432 Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
19. P087 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Impact of Ulcerative Colitis Symptoms on Daily Life
20. OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
21. P329 Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients
22. P494 Can Patients Monitor Response To Ustekinumab In The Real World?
23. P371 Using digital monitoring during the COVID pandemic to streamline outpatient appointments
24. DOP13 Artificial Intelligence (AI) in endoscopy - Deep learning for detection and scoring of Ulcerative Colitis (UC) disease activity under multiple scoring systems
25. P198 Practical deep learning tool for the scoring of ulcerative colitis disease activity in central reading
26. DOP09 Mirikizumab-induced transcriptome changes in patient biopsies at Week 12 are maintained through Week 52 in patients with Ulcerative Colitis
27. P298 Patient-reported outcomes: the ICHOM standard set for IBD in real-life practice helps quantify deficits in current care
28. P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study
29. P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis
30. P283 Patient-reported symptoms over a period of 14 days reliably predict endoscopic and histological disease activity in ulcerative colitis (UC)
31. P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
32. P619 Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission
33. P567 Could an escalation of therapy or intervention (ETI) calculator be used to triage appointments for patients with ulcerative colitis?
34. OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
35. P313 Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
36. DOP11 Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
37. P724 Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
38. P057 Gut microbiome diversity in acute severe colitis is distinct from mild-to-moderate ulcerative colitis
39. P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
40. P105 Can patients enter the ‘Standard Set’ ICHOM parameters by completing electronic questionnaires?
41. Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease
42. P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration
43. P461 Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
44. OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM
45. P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
46. P427 Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)
47. P262 New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC)
48. P152 Fertility and reproduction in a tertiary IBD centre: the Oxford experience
49. P693 Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
50. P360 TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.